ARTICLE | Company News
Takeda's vedolizumab under FDA review for UC, Crohn's
September 5, 2013 12:05 AM UTC
FDA accepted and granted Priority Review to a BLA from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for vedolizumab to treat moderately to severely active ulcerative colitis (UC). The pharma expects a ...